Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Agrippal in Healthy Adults
NCT01879553Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Primary completion
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of subunit inactivated influenza vaccine in influenza (2 arms), sponsored by Novartis. Primary endpoints: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2 at Day 22, Percentages of Subjects With Seroconversion or Significant Increase in SRH Area at Day 22 and 6 more. Started Jul 2013; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01879553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01879553.